Pubfacts - Scientific Publication Data
  • Categories
  • |
  • Journals
  • |
  • Authors
  • Login
  • Categories
  • Journals

Search Our Scientific Publications & Authors

Publications
  • Publications
  • Authors
find publications by category +
Translate page:

Olfactory system of highly trained dogs detects prostate cancer in urine samples.

Authors:
Gianluigi Taverna Lorenzo Tidu Fabio Grizzi Valter Torri Alberto Mandressi Paolo Sardella Giuseppe La Torre Giampiero Cocciolone Mauro Seveso Guido Giusti Rodolfo Hurle Armando Santoro Pierpaolo Graziotti

J Urol 2015 Apr 28;193(4):1382-7. Epub 2014 Sep 28.

Humanitas Clinical and Research Center, Rozzano, Milan, Italy.

Purpose: We established diagnostic accuracy in terms of the sensitivity and specificity with which a rigorously trained canine olfactory system could recognize specific volatile organic compounds of prostate cancer in urine samples.

Materials And Methods: Two 3-year-old female German Shepherd Explosion Detection Dogs were trained to identify prostate cancer specific volatile organic compounds in urine samples. They were tested on 362 patients with prostate cancer (range low risk to metastatic) and on 540 healthy controls with no nonneoplastic disease or nonprostatic tumor. This cross-sectional design for diagnostic accuracy was performed at a single Italian teaching hospital and at the Italian Ministry of Defense Military Veterinary Center.

Results: For dog 1 sensitivity was 100% (95% CI 99.0-100.0) and specificity was 98.7% (95% CI 97.3-99.5). For dog 2 sensitivity was 98.6% (95% CI 96.8-99.6) and specificity was 97.6% (95% CI 95.9-98.7). When considering only men older than 45 years in the control group, dog 1 achieved 100% sensitivity and 98% specificity (95% CI 96-99.2), and dog 2 achieved 98.6% sensitivity (95% CI 96.8-99.6) and 96.4% specificity (95% CI 93.9-98.1). Analysis of false-positive cases revealed no consistent pattern in participant demographics or tumor characteristics.

Conclusions: A trained canine olfactory system can detect prostate cancer specific volatile organic compounds in urine samples with high estimated sensitivity and specificity. Further studies are needed to investigate the potential predictive value of this procedure to identify prostate cancer.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.juro.2014.09.099DOI Listing
April 2015

Publication Analysis

Top Keywords

prostate cancer
24
organic compounds
12
olfactory system
12
specific volatile
12
volatile organic
12
urine samples
12
compounds urine
8
dog sensitivity
8
canine olfactory
8
specificity 95%
8
cancer specific
8
trained canine
8
cancer urine
8
diagnostic accuracy
8
sensitivity specificity
8
dog achieved
8
95% 968-996
8
identify prostate
8
95%
7
cancer
6

Keyword Occurance

Similar Publications

Optimization of ODAP-Urea-based dual-modality PSMA targeting probes for sequential PET-CT and optical imaging.

Authors:
Yuan Li Xiaojiang Duan Hongchuang Xu Jingming Zhang Haoxi Zhou Xiaojun Zhang Jinming Zhang Zhi Yang Zhenhua Hu Ning Zhang Jie Tian Xing Yang

Bioorg Med Chem 2022 May 10;66:116810. Epub 2022 May 10.

Institute of Medical Technology, Peking University Health Science Center, Beijing 100191, China; Department of Nuclear Medicine, Peking University First Hospital, Beijing 100034, China; NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals, Beijing 100142, China. Electronic address:

Prostate-specific membrane antigen (PSMA) is emerging as a promising target to specifically image prostate cancer. Dual-modality probe combining radionuclide imaging and near-infrared fluorescence navigation targeting PSMA would enable both the preoperative staging and intraoperative detection of the tumor lesions. To overcome one of the key barriers for achieving high contrast imaging at both early and late time points, we optimized the pharmacokinetics of dual-modality probes based on oxalyldiaminopropionic acid-urea (ODAP-Urea) PSMA inhibitors recently developed. Read More

View Article and Full-Text PDF
May 2022
Similar Publications

Attribution of Cancer Origins to Endogenous, Exogenous, and Preventable Mutational Processes.

Authors:
Vincent L Cannataro Jeffrey D Mandell Jeffrey P Townsend

Mol Biol Evol 2022 May;39(5)

Program in Computational Biology and Bioinformatics, Yale University, New Haven, CT, USA.

Mutational processes in tumors create distinctive patterns of mutations, composed of neutral "passenger" mutations and oncogenic drivers that have quantifiable effects on the proliferation and survival of cancer cell lineages. Increases in proliferation and survival are mediated by natural selection, which can be quantified by comparing the frequency at which we detect substitutions to the frequency at which we expect to detect substitutions assuming neutrality. Most of the variants detectable with whole-exome sequencing in tumors are neutral or nearly neutral in effect, and thus the processes generating the majority of mutations may not be the primary sources of the tumorigenic mutations. Read More

View Article and Full-Text PDF
May 2022
Similar Publications

Circulating free testosterone and risk of aggressive prostate cancer: prospective and Mendelian randomization analyses in international consortia.

Authors:
Eleanor L Watts Aurora Perez-Cornago Georgina K Fensom Karl Smith-Byrne Urwah Noor Colm D Andrews Marc J Gunter Michael V Holmes Richard M Martin Konstantinos K Tsilidis Demetrius Albanes Aurelio Barricarte H Bas Bueno-de-Mesquita Chu Chen Barbara A Cohn Niki L Dimou Luigi Ferrucci Leon Flicker Neal D Freedman Graham G Giles Edward L Giovannucci Gary E Goodman Christopher A Haiman Graeme J Hankey Jiaqi Huang Wen-Yi Huang Lauren M Hurwitz Rudolf Kaaks Paul Knekt Tatsuhiko Kubo

Int J Cancer 2022 May 17. Epub 2022 May 17.

Department of Public Health and Health Policy, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.

Previous studies had limited power to assess the associations of testosterone with aggressive disease as a primary endpoint. Further, the association of genetically predicted testosterone with aggressive disease is not known. We investigated the associations of calculated free and measured total testosterone and sex hormone-binding globulin (SHBG) with aggressive, overall and early-onset prostate cancer. Read More

View Article and Full-Text PDF
May 2022
Similar Publications

The state of the art for artificial intelligence in lung digital pathology.

Authors:
Vidya Sankar Viswanathan Paula Toro Germán Corredor Sanjay Mukhopadhyay Anant Madabhushi

J Pathol 2022 May 17. Epub 2022 May 17.

Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, USA.

Lung diseases carry a significant burden of morbidity and mortality worldwide. The advent of digital pathology (DP) and an increase in computational power have led to the development of artificial intelligence (AI) based tools that can assist pathologists and pulmonologists in improving clinical workflow and patient management. While previous works have explored the advances in computational approaches for breast, prostate, and head and neck cancers, there has been a growing interest in applying these technologies to lung diseases as well. Read More

View Article and Full-Text PDF
May 2022
Similar Publications

IMRT and SBRT Treatment Planning Study for the First Clinical Biology-Guided Radiotherapy System.

Authors:
Daniel Pham Eric Simiele Dylan Breitkreutz Dante Capaldi Bin Han Murat Surucu Seyi Oderinde Lucas Vitzthum Michael Gensheimer Hilary Bagshaw Alex Chin Lei Xing D T Chang Natalyia Kovalchuk

Technol Cancer Res Treat 2022 Jan-Dec;21:15330338221100231

Department of Radiation Oncology, 6429Stanford University, Stanford, CA, USA.

The first clinical biology-guided radiation therapy (BgRT) system-RefleXion X1-was installed and commissioned for clinical use at our institution. This study aimed at evaluating the treatment plan quality and delivery efficiency for IMRT/SBRT cases without PET guidance. A total of 42 patient plans across 6 cancer sites (conventionally fractionated lung, head, and neck, anus, prostate, brain, and lung SBRT) planned with the Eclipse treatment planning system (TPS) and treated with either a TrueBeam or Trilogy were selected for this retrospective study. Read More

View Article and Full-Text PDF
May 2022
Similar Publications
}
© 2022 PubFacts.
  • About PubFacts
  • Privacy Policy
  • Sitemap